Home

Results 1 - 10 of 178,107 for instance squalene. Search took 0.814 seconds.  
Sort by date/Sort by relevance
Why is squalene added to vaccines? Squalene is a component of some adjuvants that are added to vaccines to enhance the immune response. (...) More information What is the relevance of anti-squalene antibodies and are these linked to squalene in vaccines? (...) Detection of antibodies to squalene III. Naturally occurring antibodies to squalene in humans and mice.
Language:English
Score: 2267336.3 - https://www.who.int/vaccine_sa...lene/questions_and_answers/en/
Data Source: un
Squalene alone is not an adjuvant, but emulsions of squalene with surfactants enhance the immune response when added to antigens. (...) Most adults, particularly older ones, irrespective of their history of vaccination, have naturally occurring antibodies reacting with squalene. In a clinical trial, immunization with the licensed influenza vaccine containing squalene did not affect the frequency or titre of anti-squalene antibodies. The Committee concurred that fears of squalene in vaccine-inducing pathological anti-squalene antibodies are unfounded.
Language:English
Score: 2140201.8 - https://www.who.int/vaccine_sa...committee/reports/Jun_2006/en/
Data Source: un
WHO | Squalene-based adjuvants in vaccines Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. عربي 中文 English Français Русский Español Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Coronavirus disease (COVID-19) Ebola virus disease Air pollution Hepatitis Top 10 causes of death World Health Assembly » Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Democratic Republic of the Congo »   Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Timeline: WHO's COVID-19 response »   Emergencies Focus on » COVID-19 pandemic Ebola virus disease outbreak DRC 2021 Syria crisis Crisis in Northern Ethiopia Afghanistan Crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Coronavirus disease outbreak (COVID-19) » WHO © Credits Data Data at WHO » Global Health Estimates Health SDGs Mortality Triple billion targets Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Equity monitor Mortality Highlights » GHO SCORE Insights and visualizations Data collection tools Reports World Health Statistics 2021 » WHO © Credits About WHO About WHO » People Teams Structure Partnerships Collaborating Centres Networks, committees and advisory groups Transformation Contact us » Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Our Work » General Programme of Work WHO Academy Activities Initiatives Better health for everyone » WHO © Credits Skip to main content Access Home Alt+0 Navigation Alt+1 Content Alt+2 Global Vaccine Safety Menu Global Vaccine Safety Global Vaccine Safety Initiative Detection Investigation Communication Tools and methods Regulatory framework Technical support and trainings Global analysis and response Public-private information exchange Global Advisory Committee on Vaccine Safety Topics Committee reports Reference documents and publications Squalene-based adjuvants in vaccines Committee reports 14 July 2006 - Safety of Squalene (from meeting of 6-7 June 2006) Related links Questions and answers Page last updated: 21 July 2006 Page last reviewed: 12 January 2011 Contact us Essential Medicines and Health Products World Health Organization 20 avenue Appia 1211 Geneva 27 Switzerland Email: [email protected] You are here: Vaccine Safety The Global Advisory Committee on Vaccine Safety Topics Adjuvants Squalene-based adjuvants in vaccines Regions Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific About us Careers Library Procurement Publications Frequently asked questions Contact us Subscribe to our newsletters Privacy Legal Notice © 2022 WHO
Language:English
Score: 1994078.5 - https://www.who.int/vaccine_sa.../topics/adjuvants/squalene/en/
Data Source: un
A WHO website on adjuvants in clinical evaluation including adjuvant safety, with a database of clinical trials, will be made available shortly. Since a squalene-containing adjuvant is already used for one already licensed flu vaccine, and is also a candidate adjuvant for pandemic influenza vaccines, it would be important to assure the safety of squalene in that context.
Language:English
Score: 1707743.6 - https://www.who.int/vaccine_sa.../topics/adjuvants/Dec_2005/en/
Data Source: un
عربي 中文 English Français Русский Español Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Coronavirus disease (COVID-19) Ebola virus disease Air pollution Hepatitis Top 10 causes of death World Health Assembly » Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Democratic Republic of the Congo »   Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Timeline: WHO's COVID-19 response »   Emergencies Focus on » COVID-19 pandemic Ebola virus disease outbreak DRC 2021 Syria crisis Crisis in Northern Ethiopia Afghanistan Crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Coronavirus disease outbreak (COVID-19) » WHO © Credits Data Data at WHO » Global Health Estimates Health SDGs Mortality Triple billion targets Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Equity monitor Mortality Highlights » GHO SCORE Insights and visualizations Data collection tools Reports World Health Statistics 2021 » WHO © Credits About WHO About WHO » People Teams Structure Partnerships Collaborating Centres Networks, committees and advisory groups Transformation Contact us » Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Our Work » General Programme of Work WHO Academy Activities Initiatives Better health for everyone » WHO © Credits Skip to main content Access Home Alt+0 Navigation Alt+1 Content Alt+2 Global Vaccine Safety Menu Global Vaccine Safety Global Vaccine Safety Initiative Detection Investigation Communication Tools and methods Regulatory framework Technical support and trainings Global analysis and response Public-private information exchange Global Advisory Committee on Vaccine Safety Topics Committee reports Reference documents and publications Adjuvants Committee reports 27 July 2012 - Aluminium adjuvants (from meeting of 6-7 June 2012) 13 January 2006 - Safety of adjuvants (from meeting of 1-2 December 2005) 7 January 2005 - Safety of adjuvants (from meeting of 2-3 December 2004) 16 July 2004 - Safety of adjuvants (from meeting of 10-11 June 2004) More information on aluminium-containing vaccines and macrophagic myofasciitis More information on the safety of squalene Page last updated: 21 July 2006 Page last reviewed: 07 April 2014 Contact us Essential Medicines and Health Products World Health Organization 20 avenue Appia 1211 Geneva 27 Switzerland Email: [email protected] You are here: Vaccine Safety The Global Advisory Committee on Vaccine Safety Topics Adjuvants Regions Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific About us Careers Library Procurement Publications Frequently asked questions Contact us Subscribe to our newsletters Privacy Legal Notice © 2022 WHO
Language:English
Score: 1369220.5 - https://www.who.int/vaccine_sa...committee/topics/adjuvants/en/
Data Source: un
A WHO website on adjuvants in clinical evaluation including adjuvant safety, with a database of clinical trials, will be made available shortly. Since a squalene-containing adjuvant is already used for one already licensed flu vaccine, and is also a candidate adjuvant for pandemic influenza vaccines, it would be important to assure the safety of squalene in that context.
Language:English
Score: 1324222.95 - https://www.who.int/vaccine_sa...committee/reports/Dec_2005/en/
Data Source: un
Full report in WER pdf, 281kb html version 6-7 June 2006 meeting Vaccine safety monitoring and the WHO Programme for International Drug Monitoring; Post-marketing surveillance of rotavirus vaccines; Safety of squalene; Immunogenic overload; Safety of pandemic influenza vaccines; Safety issues of varicella vaccines; Modus operandi of the Committee and additional information Full report in WER pdf, 241kb html version 1-2 December 2005 meeting Vaccine Safety Net; Safety issues associated with pandemic influenza vaccines; Safety of adjuvants; Rotavirus vaccine safety; Subacute sclerosing panencephalitis and measles vaccination; Chronic fatigue syndrome and hepatitis B vaccination; Conjugate meningococcal vaccine and Guillain-Barré Syndrome; Modus operandi of the Committee.
Language:English
Score: 818615.9 - https://www.who.int/vaccine_safety/committee/reports/en/
Data Source: un
"Recommendation X.739":scannerId GET, bBE REPLACE-WITH-DEFAULT GET, eS REPLACE-WITH-DEFAULT GET, sES REPLACE-WITH-DEFAULT GET ; ; ; CONDITIONAL PACKAGES cSESCurrentDataPackage PRESENT IF "an instance supports it", farEndCSESCurrentDataPackage PRESENT IF "an instance supports it" , uASCurrentDataPackage PRESENT IF "an instance supports it", farEndCurrentDataPackage PRESENT IF "monitoring of the far end is supported and the monitored point is Bidirectional" ; REGISTERED AS {g774-01MObjectClass 9}; 2. (...) Replacement with: opticalSourceSPICurrentData MANAGED OBJECT CLASS DERIVED FROM sdhCurrentData; CHARACTERIZED BY opticalSourceSPICurrentDataPackage PACKAGE BEHAVIOUR opticalSourceSPICurrentDataBehaviour; ; ; CONDITIONAL PACKAGES transmitPowerLevelCurrentDataPackage PRESENT IF "an instance supports it", transmitPowerLevelTideMarkPackage PRESENT IF "an instance supports it and transmitPowerLevelCurrentDataPackage is present", laserBiasCurrentDataPackage PRESENT IF "an instance supports it", laserBiasTideMarkPackage PRESENT IF "an instance supports it and laserBiasCurrentDataPackage is present", laserTemperatureCurrentDataPackage PRESENT IF "an instance supports it", laserTemperatureTideMarkPackage PRESENT IF "an instance supports it and laserTemperatureCurrentDataPackage is present" ; REGISTERED AS {g774-01MObjectClass 5}; 7. Replacement with: opticalSourceSPICurrentData MANAGED OBJECT CLASS DERIVED FROM sdhCurrentData; CHARACTERIZED BY opticalSourceSPICurrentDataPackage PACKAGE BEHAVIOUR opticalSourceSPICurrentDataBehaviour; ATTRIBUTES "Recommendation X.739":scannerId GET ; ; ; CONDITIONAL PACKAGES transmitPowerLevelCurrentDataPackage PRESENT IF "an instance supports it", transmitPowerLevelTideMarkPackage PRESENT IF "an instance supports it and transmitPowerLevelCurrentDataPackage is present", laserBiasCurrentDataPackage PRESENT IF "an instance supports it", laserBiasTideMarkPackage PRESENT IF "an instance supports it and laserBiasCurrentDataPackage is present", laserTemperatureCurrentDataPackage PRESENT IF "an instance supports it", laserTemperatureTideMarkPackage PRESENT IF "an instance supports it and laserTemperatureCurrentDataPackage is present" ; REGISTERED AS {g774-01MObjectClass 5};
Language:English
Score: 656159.1 - https://www.itu.int/wftp3/Publ...u-t/g/g774.1/2001/CHANGES.html
Data Source: un
An instance of this object class is pointed to by a reliableResourcePointer attribute in a instance of the sdhRadioProtectionUnit object class. The crossConnectionObjectPointer attribute in an instance of this object class points to its associated sdhRadioProtectionUnit instance which has the reliableResourcePointer attribute pointing back to the instance of this object class. (...) An instance of this object class is pointed to by a reliableResourcePointer attribute in a instance of the sdhRadioProtectionUnit object class.
Language:English
Score: 653056.5 - https://www.itu.int/wftp3/Publ...tu-t/g/g774.8/2001/g774.8.html
Data Source: un
An instance of this object class is pointed to by a reliableResourcePointer attribute in a instance of the sdhRadioProtectionUnit object class. The crossConnectionObjectPointer attribute in an instance of this object class points to its associated sdhRadioProtectionUnit instance which has the reliableResourcePointer attribute pointing back to the instance of this object class. (...) An instance of this object class is pointed to by a reliableResourcePointer attribute in a instance of the sdhRadioProtectionUnit object class.
Language:English
Score: 653056.5 - https://www.itu.int/wftp3/Publ...itu-t/g/g774.8/2001/g774.8.gdm
Data Source: un